331. 特発性多中心性キャッスルマン病 Idiopathic multicentric castleman disease Clinical trials / Disease details
臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03043105 (ClinicalTrials.gov) | January 1, 2017 | 31/1/2017 | TCP Regimen in Newly Diagnosed MCD:a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Thalidomide, Cyclophosphamide and Prednisone in Newly Diagnosed Multicentric Castleman's Disease: a Prospective, Single-center, Single-arm, Phase-II Pilot Trial | Multicentric Castleman Disease | Drug: Thalidomide, cyclophosphamide and prednisone | Peking Union Medical College Hospital | NULL | Active, not recruiting | 18 Years | N/A | All | 25 | Phase 2 | China |